Boston Scientific
30-Second Executive Brief
Executive Assessment
Boston Scientific functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A cardiovascular and medical-device company that cut its 2026 revenue growth guidance from 7-8.5% to 5.5-6.5% after Q2 2026 results beat consensus estimates but revealed an unexpected slowdown in its US WATCHMAN left atrial appendage closure business and intensified US electrophysiology competition. Boston Scientific reported Q2 2026 net sales of $5.442 billion (up 7.5% reported), committed $1.5 billion to invest in TAVR developer MiRus, and launched a restructuring program targeting approximately $500 million in run-rate savings exiting 2029.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Federal contract disclosures
Department of Veterans Affairs — $4,035,840: Y90 GLASS MICROSPHERES
USAspending.gov · Apr 23, 2022
Department of Veterans Affairs — $2,920,340: THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION
USAspending.gov · Oct 1, 2022
Department of Veterans Affairs — $1,364,595: Y90 THERASPHERE
USAspending.gov · Apr 1, 2024
Department of Veterans Affairs — $1,283,404: CARDIAC HOLSTER MONITORING SERVICES
USAspending.gov · Sep 30, 2023
Department of Veterans Affairs — $954,240: VAPAHCS THERASPHERE Y90 RADIOPHARMACEUTICALS
USAspending.gov · Oct 1, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- MassDevice — Boston Scientific cuts 2026 guidance again despite Q2 beatsnews
Latest Activity
- FilingBoston Scientific filed an 8-K (items 1.05)8-K
- FilingBoston Scientific filed an 8-K (items 8.01)8-K
- FilingBoston Scientific filed an 8-K (items 2.02,9.01)8-K
- FilingBoston Scientific filed an 8-K (items 2.05)8-K
- FilingBoston Scientific insider buying — $2,999,973 purchaseForm 4
- FilingBoston Scientific insider buying — $10,072,631 purchaseForm 4
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Boston Scientific — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
A second consecutive 2026 guidance cut despite a Q2 earnings beat is a credibility problem, not just a WATCHMAN-specific issue
32% confidenceBoston Scientific cut full-year 2026 revenue growth guidance from 7-8.5% to 5.5-6.5% -- its second guidance reduction of the year -- even though Q2 2026 net sales of $5.442 billion beat consensus estimates, citing WATCHMAN slowdown and electrophysiology competition.
This is InsightNodes' own interpretive read: when a company beats quarterly consensus but still cuts full-year guidance for a second consecutive time, it signals management's forward visibility into specific franchises (WATCHMAN, electrophysiology) has genuinely deteriorated rather than the company simply being conservative -- this pattern typically weighs more heavily on investor confidence than the guidance cut's magnitude alone, since repeated misses on forward-looking commentary make each subsequent guidance number less trustworthy until the company demonstrates it can hit what it forecasts.
InsightNodes analysis of Boston Scientific Q2 2026 results · Aug 14, 2026
Boston Scientific's Timeline
A sourced, dated history of Boston Scientific's key moments — founding to present.
Jul 2026 · Q2 2026: revenue beats, but guidance cut
Boston Scientific reported Q2 2026 net sales of $5.442 billion (up 7.5% reported) ahead of consensus, but cut full-year 2026 revenue growth guidance to 5.5-6.5% citing WATCHMAN slowdown and EP competitive pressure.
Jul 2026 · Invests $1.5 billion in TAVR developer MiRus
Boston Scientific committed $1.5 billion to invest in TAVR (transcatheter aortic valve replacement) developer MiRus.